Navigation Links
For Patients Who Fail on Viagra, Levitra or Cialis
Date:10/29/2008

TriMix Laboratories Announces Major Product Enhancement

CHERRY HILL, N.J., Oct. 29 /PRNewswire/ -- TriMix Laboratories LLC today announced a major enhancement to their flagship product TriMix-gel(TM). TriMix-gel(TM) uses the ED gel(TM) (pat. pend.) applicator system. The applicator has been fitted with an adapter to make the use of TriMix-gel(TM) even easier for the patient. The adapter will be included for shipment to patients immediately.

The new adapter is featured on the website http://www.trimixgel.com. A video there includes a demonstration of an actual patient applying the medicine. TriMix Laboratories President T.J. Harkins says, "The innovative nature of the TriMix-gel(TM) applicator makes it hard to describe in a small sound bite. This video is an important tool in helping ED patients understand how valuable TriMix-gel(TM) can be for them."

TriMix-gel(TM) has been used by doctors as an alternative erectile dysfunction (ED) treatment. Doctors prescribe TriMix-gel(TM) for patients who have failed on Viagra, Levitra or Cialis type tablets or who cannot tolerate their side effects. Trimix ingredients have been tested and widely prescribed for many years for improvement of sexual health.

TriMix-gel(TM) contains active ingredients which are classified as medicine and are listed in the US Pharmacopoeia. Therefore, a patient would need a prescription from his physician to obtain TriMix-gel(TM). For an order form, visit http://www.trimixgel.com and click the prescription form. The patient gives the form to the doctor. The doctor faxes the prescription to the pharmacy at 877-387-4649 and the pharmacy ships the medicine directly to the patient.

Typically, the trimix liquid for injection version of the compound would have to be refrigerated and then self injected with a needle at time of use. But the compound in gel form, called TriMix-gel(TM), allows the patient to carry the medicine at room temperature. More importantly, an ED patient will not have to use a needle to self inject before sexual intercourse.

Recently, clinical trials were performed on TriMix-gel(TM). All the test patients were men who failed on Viagra, Levitra or Cialis tablets. These patients were given TriMix-gel(TM). All the test patients received some degree of positive effect from TriMix-gel(TM) in the form of tumescence (enlargement). It was determined that 40% of the test patients achieved a result sufficient for sexual intercourse over Viagra, Levitra or Cialis tablets.

The trial results were published in the Journal of Urology Supplement, J. Urol. 179 (4): 431, 2008. For more information, visit http://www.trimixgel.com and click "Drug Studies."

TriMix Laboratories President T.J. Harkins said, "Our test patients were very impressed with the 'ease of use.' We are happy our new adapter is so well received."

TriMix Laboratories LLC is a medical research and marketing firm specializing in the urological subspecialty of erectile dysfunction. The information contained herein is general in nature and is intended for use only as an informational aid. It does not cover all possible uses, actions, precautions, side effects, or interactions of the products shown, nor is the information intended as medical advice or diagnosis for individual health problems. TriMix-gel(TM) has not been evaluated by the Food and Drug Administration ("FDA"). TriMix-gel(TM) is not made under GMP requirements. It is compounded in a licensed compounding pharmacy for the use of an individual patient who has been prescribed TriMix-gel(TM) by a licensed physician. It is not intended for making an evaluation as to the risks and benefits. Before taking any action, consult your Doctor.

Contact: T.J. Harkins

TriMix Laboratories

Cherry Hill, NJ

856-428-7008


'/>"/>
SOURCE TriMix Laboratories LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
2. Comparison of obstetric outcomes between on-call and patients own obstetricians
3. Vision restoration therapy shown to improve brain activity in brain injured patients
4. Diabetes appears to increase risk of death for patients with acute coronary syndromes
5. Ambulatory oxygen rarely a benefit in COPD patients without resting hypoxemia
6. Restricting Blood Flow May Help Heart Bypass Patients
7. Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer
8. Study provides hope that some transplant patients could live free of antirejection drugs
9. Study provides hope that some transplant patients could live free of anti-rejection drugs
10. Longer ambulance journeys boost death risk for seriously ill patients
11. Expenses Overshadow Optimism for Kidney Failure Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Planet Fitness, ... the U.S., announced today its plans to open a flagship location in Covington, LA ... the former Rooms To Go store next to Office Depot in the Holiday Square ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... Hair Restoration, has recently contributed a medical article to the newly revamped ... Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit ...
(Date:10/12/2017)... ... , ... On Saturday, October 21, the Health & Wellness Center at Florida ... money for the American Heart Association Heart Walk. Teams of up to 10 people ... keep their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... $3,296 in property taxes a year. In some states—like New York, New Jersey, ... By contrast, many overseas retirement havens have extremely low property-tax rates, which contributes ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that ... developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and ...
(Date:9/18/2017)... , Sept. 18, 2017 ... fields of bioinformatics and immune engineering, today ... protective avian influenza A (H7N9) vaccine. ... related to seasonal influenza and presents a ... on prior exposure to be effective. Using ...
Breaking Medicine Technology: